HIV - antiretroviral initiation & long-term management
ART start · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Lifelong combination antiretroviral therapy (ART) is offered to all people with HIV regardless of CD4 count, started rapidly (same-day where feasible) to suppress viraemia, restore immunity and prevent transmission (U=U). An integrase inhibitor-based regimen is first line for most.
Red flags
- CD4 under 100 with headache or visual change (cryptococcal/toxoplasma)
- New respiratory failure after ART start (PCP, IRIS)
- Jaundice or rising transaminases
- Features of disseminated TB
- Severe rash with mucosal involvement or systemic features
Assessment
Differential diagnosis
- Acute seroconversion illness
- Advanced HIV with opportunistic infection
- Immune reconstitution inflammatory syndrome
- ART failure / resistance
- Drug toxicity mimicking disease
- Co-infection (TB, hepatitis B/C)
Investigations
- Confirmatory HIV antigen/antibody plus viral load
- CD4 count and percentage
- HIV genotypic resistance test (baseline)
- HLA-B*5701 before abacavir
- Hepatitis B surface antigen, hepatitis C antibody, hepatitis A immunity
- Renal and liver profile, lipids, HbA1c, pregnancy test
- Screen for latent TB and STIs
Management
- Confirm diagnosis and counsel; assess readiness and disclose U=U concept
- Exclude or treat cryptococcal and TB disease before rapid start if CD4 very low or symptomatic
- Send baseline bloods including genotype, HLA-B*5701, hepatitis serology, CD4, viral load
- Choose a first-line integrase-inhibitor regimen; offer same-day or within-7-day start if ready
- Avoid dolutegravir drug interactions (antacids, polyvalent cations, rifampicin dose adjustment)
- Screen and vaccinate (hepatitis B, pneumococcal, influenza, COVID-19, HPV, mpox where indicated)
- Start opportunistic-infection prophylaxis per CD4 threshold
- Review adherence and tolerability at 2-4 weeks
- Repeat viral load at 4-8 weeks then 3-6 monthly; target undetectable by 24 weeks
- Monitor for immune reconstitution inflammatory syndrome in the first weeks
- Arrange long-term monitoring of renal, bone, metabolic and cardiovascular risk
- Link to specialist HIV service for continuity
Drugs & doses
Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg PO once daily
Dolutegravir 50 mg PO once daily plus emtricitabine/tenofovir (alternative backbone)
Dolutegravir/lamivudine 50/300 mg PO once daily (two-drug regimen if eligible)
Co-trimoxazole 960 mg PO once daily if CD4 under 200 (PCP prophylaxis)
Dolutegravir 50 mg PO twice daily if co-administered with rifampicin
Disposition
Outpatient specialist HIV clinic; admit if opportunistic infection or severe toxicity; urgent ID input for advanced disease.
Complications & pitfalls
- Immune reconstitution inflammatory syndrome
- Drug toxicity (renal, hepatic, hypersensitivity, weight gain)
- Virological failure and resistance
- Opportunistic infection before immune recovery
- Drug-drug interactions causing subtherapeutic levels
Exam pearls
- Undetectable equals untransmittable (U=U) once suppressed and sustained
- Dolutegravir is preferred in pregnancy with no meaningful neural-tube signal on current data
- Tenofovir-containing regimens also treat hepatitis B co-infection; do not stop abruptly
- Rapid/same-day start improves linkage and viral suppression
- Check for cryptococcal antigen if CD4 under 100 before starting
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.